Status:
COMPLETED
The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring
Lead Sponsor:
University of Geneva, Switzerland
Collaborating Sponsors:
University Hospital, Geneva
Conditions:
Beta-lactam Antibiotics
Therapeutic Drug Monitoring
Eligibility:
All Genders
18+ years
Brief Summary
Little is known of beta-lactam antibiotics' true therapeutic plasma concentration range. The aims of this study are to define evidence-based, safe and effective upper and lower limits of the plasma co...
Detailed Description
Little is known of beta-lactam antibiotics' true therapeutic plasma concentration range. The aims of this study are to define evidence-based, safe and effective upper and lower limits of the plasma co...
Eligibility Criteria
Inclusion
- \- Hospitalized patients with suspected or confirmed systemic bacterial infection:
- Receiving either imipenem-cilastatin, meropenem, amoxicillin (±clavulanic acid), flucloxacillin, piperacillin-tazobactam, ceftazidime or cefepime
- Aged ≥18 years
- Requiring intensive or intermediate-intensive (step-down) care OR severely immunosuppressed (see definitions)
Exclusion
- Planned imminent transfer to an outside hospital
- Poor prognosis with life expectancy \<1 week and/or intended transition to palliative care
Key Trial Info
Start Date :
January 14 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
771 Patients enrolled
Trial Details
Trial ID
NCT03790631
Start Date
January 14 2019
End Date
December 31 2023
Last Update
May 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Geneva University Hospitals
Geneva, Canton of Geneva, Switzerland, 1205